
GSK head joins Nabriva as chief medical officer
pharmafile | May 26, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Elyse Seltzer, GSK, Nabriva Therapeutics
Austrian-based clinical stage biopharma firm Nabriva Therapeutics has appointed Dr Elyse Seltzer as its chief medical officer.
Seltzer assumes the role from Dr William Prince, who will transition to senior vice president of its clinical science division.
She joins Nabriva from GlaxoSmithKline where she was vice president of global clinical sciences and operations, and prior to joining GSK was chief medical officer at Tengion, a regenerative medicine company.
Seltzer has also held roles at Centocor and Vicuron, but began her in the anti-infectives clinical R&D unit at SmithKline Beecham (now GSK).
Dr Colin Broom who is the firm’s chief executive, says: “We are very pleased to welcome Elyse to Nabriva. We have established a world class clinical development leadership team to advance our pipeline with a sense of urgency to address areas of significant medical need.”
Seltzer adds: “I am thrilled to join Nabriva. I am excited to have the opportunity to advance a novel class of antibacterials, particularly given the current and evolving challenges around resistance to currently available antibiotics. I look forward to working with the highly experienced clinical team to fulfil this goal.”
Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …





